SCHEMBL5542889

SCHEMBL5542889

[CH2]c1cc2[nH]c(=O)oc2cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.72
NOS1 P29475 4/20 0.53
NOS3 P29474 3/20 0.53
NOS2 P35228 3/20 0.53
TSHR P16473 3/20 0.53
LMNA P02545 2/20 0.53
CYP1A2 P05177 2/20 0.53
THPO P40225 2/20 0.53
BLM P54132 2/20 0.53
ADRA2A P08913 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
LRRK2 Q5S007 1/20 0.42
OGT O15294 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
PDE3B Q13370 2/20 0.39
PDE3A Q14432 2/20 0.39
GRIA1 P42261 2/20 0.37
CACNG8 Q8WXS5 1/20 0.37
CREBBP Q92793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536703 0.93 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL11256608 0.84 KMO (1.00) KMONOS1NOS3NOS2TSHR
SCHEMBL29902368 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL5542896 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL5536553 0.78 KMO (0.52) KMONOS1NOS3NOS2TSHR
SCHEMBL11045421 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL783644 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL12420056 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL5543204 0.78 KMO (0.52) KMONOS1NOS3NOS2TSHR
SCHEMBL30295627 0.75 KMO (0.68) KMONOS1NOS3NOS2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMO 4404/4885NOS1 553/4885NOS3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.